focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

AIM WINNERS & LOSERS: Windward sees high contracting activity levels

Thu, 12th Oct 2023 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Windward Ltd, up 16% at 72.50 pence, 12-month range 33.00p-80p. The Tel Aviv, Israel-based maritime predictive intelligence company announces numerous contract wins, and says it is trading in line with market expectations for 2023. Says the typical pattern of seeing a high level of US governmental contracting activity in the second half. The Rest of World Government segment also performs well, with four new contract. Says Nigerian government contract renewed as expected, with USD1 million of annual contract value added per year over three years. Also notes continued growth of its Commercial sector customer base.

----------

Norman Broadbent PLC, up 25% at 6.85p, 12-month range 3.00p-6.93p. The professional services company reports that the third quarter was "its strongest quarterly performance since well before the onset of Covid-19", despite summer months typically seeing softer trade. In its third quarter, revenue jumped 60% year-on-year to GBP3.2 million, as net fee income rose 65% to GBP2.8 million. Now is confident of delivering and exceeding its prior target of GBP1.3 million earnings before interest, tax, depreciation and amortisation by 2025. "The investments made in our people, processes and supporting technologies have begun to deliver encouraging results and we have ambitious and sustainable growth plans," says CEO Kevin Davidson.

----------

AIM - LOSERS

----------

Shield Therapeutics PLC, down 6.4% at 6.27p, 12-month range 5.80p-12.85p. The commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer says its chief financial officer, Hans-Peter Rudolf, is leaving to pursue other opportunities. Rudolf will leave next Friday. The firm's company controller, Paul Spoors, will take on the CFO role on an interim basis. Shield says it has engaged an executive search firm to identify a new CFO.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
30 Apr 2024 19:54

EARNINGS AND TRADING: Software Circle & Beximco report higher revenue

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

21 Feb 2024 16:57

LONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors anxiously look ahead to this evening's Federal Open Market Committee ...

21 Feb 2024 12:36

Shield Therapeutics sinks as strong performance marred by data issues

(Alliance News) - Shield Therapeutics PLC on Wednesday said that it was expecting stellar results for 2023, but this success was overshadowed by a mis...

9 Jan 2024 11:33

IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO

Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag as chief financ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.